SecBot SecBot

HCM

HUTCHMED (China) Ltd
Nasdaq· Pharmaceutical Preparations· Inc. E9· CIK 0001648257 Biotech & Drug Discovery
$14.73 −0.17 (−1.14%)
Nov 16 4:00 PM ET · prev $14.90
Market cap
$2.6B
Mid cap
Median target
$19.50
+32% · range $13.60–33.27
1 year
0.0%
from $14.73 · Nov 17
30 days
+3.9%
from $14.18
52-week range
$9.99–16.05
−8% from high · low Jun 22
Avg volume 20D
48.3K
Nov 6 spike 157.3K
Short interest
275.4K
≈0.2% of shares · +3.9%
Days to cover
7.6
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Reddit crowd
50°
Neutral · 1 mention this week
Filing reports
20
analyzed by SecBot
SecBot read BULLISH 17 reports · 90 days
Balance 0 bearish · 14 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 16/17

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q3 2026: 8 added (0 new), 7 trimmed or exited.

  • Short sellersSTEADY

    Short interest +3.9% to 275.4K shares. 7.6 days to cover, ≈0.2% of shares.

  • TrendUPTREND

    5% above its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
AmundiTRIM134,631$2.0M
BNP PARIBAS FINANCIAL MARKETSTRIM72,998$1.1M
UBS Group AGADD66,537$973.4K
JPMORGAN CHASE & CODOUBLED48,851$691.2K
Mariner, LLCADD13,502$197.3K
OSAIC HOLDINGS, INC.DOUBLED1,777$26.0K
Rockefeller Capital Management L.P.TRIM709$10.4K
Arax Advisory PartnersADD505$7.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jul 2026
12-month targets · 12 analysts

Price is inside the target range. Median implies +32%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Jul 23, 2026Goldman Sachs
MAINTAIN
MAINTAINNeutral
Jul 7, 2026B of A Securities
MAINTAIN
MAINTAINBuy
Reddit
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 1 1 in posts · 0 in comments
Recent posts
All social signals and their track records

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
May 20, 2026
Chiu Lorenso
Deputy Chief Financial Officer
May 20, 2026
OTHER5,176 sh
May 20, 2026
Chiu Lorenso
Deputy Chief Financial Officer
May 20, 2026
OTHER8,863 sh
May 20, 2026
Su Wei-guo
CEO and CSO
May 20, 2026
OTHER132,864 sh
May 20, 2026
Su Wei-guo
CEO and CSO
May 20, 2026
OTHER75,140 sh
May 20, 2026
Nixon Charles George Rupert
Group General Counsel
May 20, 2026
OTHER7,445 sh
May 20, 2026
Nixon Charles George Rupert
Group General Counsel
May 20, 2026
OTHER7,644 sh
May 20, 2026
Cheng Chig Fung
Acting CEO and CFO
May 20, 2026
OTHER30,157 sh
May 20, 2026
Cheng Chig Fung
Acting CEO and CFO
May 20, 2026
OTHER26,307 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current QNoneNoneNo data$0.00
Next QNoneNoneNo data$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
275,359
shares short
+3.9%
vs prior settlement
7.6
days to cover
≈0.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent
Nov 15, 2026
Contract
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 15, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13)…
Nov 5, 2026
Press release
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval
Nov 2, 2026
Regulatory
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
Follows US FDA new drug application submission in September 2026, marking important global regulatory progress
Oct 29, 2026
Press release
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia
Oct 27, 2026
Company news
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13)…

SecBot reports

20 filings · 13 press releases · 14 bullish · 0 bearish · 6 neutral
All HCM filing & press-release reports (33)